Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Cited by (565)

Items 101–200 of 565

1. Amyotrophic Lateral Sclerosis: Proteins, Proteostasis, Prions, and Promises
   Luke McAlary, Yee Lian Chew, Jeremy Stephen Lum, Nicholas J. Geraghty, Justin J. Yerbury, Neil R. Cashman · 2020 · Frontiers in Cellular Neuroscience
2. APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology
   Chemparathy, Augustine, Le Guen, Yann, Chen, Sunny, Lee, Eun-Gyung, Leong, Lesley, Gorzynski, John E., Jensen, Tanner D., Ferrasse, Alexis, Xu, Guangxue, Xiang, Hong et al. · 2024 · Neuron
3. Translational Approaches for Brain Delivery of Biologics via Cerebrospinal Fluid
   Shraddha Sadekar, Mayumi Bowen, Hao Cai, Samira Jamalian, Hanine Rafidi, Whitney Shatz-Binder, Julien Lafrance‐Vanasse, Pamela Chan, William J. Meilandt, Amy Oldendorp et al. · 2022 · Clinical Pharmacology & Therapeutics
4. Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives
   Jan Lejman, Kinga Panuciak, Emilia Nowicka, Angelika Mastalerczyk, Katarzyna Wojciechowska, Monika Lejman · 2023 · International Journal of Molecular Sciences
5. Multiomics and machine-learning identify novel transcriptional and mutational signatures in amyotrophic lateral sclerosis
   Alberto Catanese, Sandeep Rajkumar, Daniel Sommer, Pegah Masrori, Nicole Hersmus, Philip Van Damme, Simon Witzel, Albert Christian Ludolph, Ritchie Ho, Tobias M. Boeckers et al. · 2023 · Brain
6. Opinion: more mouse models and more translation needed for ALS
   Elizabeth Fisher, Linda Greensmith, Andrea Malaspina, Pietro Fratta, Michael G. Hanna, Giampietro Schiavo, Adrian M. Isaacs, Richard W. Orrell, Thomas J. Cunningham, Abraham Acevedo‐Arozena · 2023 · Molecular Neurodegeneration
7. Therapies in preclinical and clinical development for Angelman syndrome
   Theodora Markati, Jessica B. Duis, Laurent Servais · 2021 · Expert Opinion on Investigational Drugs
8. Sensory Involvement in Amyotrophic Lateral Sclerosis
   M.Á. Rubio, Mireia Herrando‐Grabulosa, Xavier Navarro · 2022 · International Journal of Molecular Sciences
9. Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis—a cross‐sectional multicenter study
   Thomas Meyer, Erma Salkic, Torsten Grehl, Ute Weyen, Dagmar Kettemann, Patrick Weydt, René Günther, Paul Lingor, Jan Christoph Koch, Susanne Petri et al. · 2023 · European Journal of Neurology
10. Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade
    Silvia Cantara, Giorgia Simoncelli, Claudia Ricci · 2024 · International Journal of Molecular Sciences
11. Overview of current and emerging therapies for amytrophic lateral sclerosis
    Jack J. Chen, PharmD, BCPS, BCGP, FASCP, FCCP; · 2020 · The American Journal of Managed Care
12. Micro-RNAs Shuttled by Extracellular Vesicles Secreted from Mesenchymal Stem Cells Dampen Astrocyte Pathological Activation and Support Neuroprotection in In-Vitro Models of ALS
    Francesca Provenzano, Sophie Nyberg, Debora Giunti, Carola Torazza, Benedetta Parodi, Tiziana Bonifacino, Cesare Usai, Nicole Kerlero de Rosbo, Marco Milanese, Antonio Uccelli et al. · 2022 · Cells
13. Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial
    Gilbert Bensimon, P. Nigel Leigh, Timothy I. M. Tree, Andrea Malaspina, Christine Payan, Hang‐Phuong Pham, Pieter Klaassen, Pamela J. Shaw, Ahmad Al Khleifat, Maria del Mar Amador et al. · 2025 · The Lancet
14. Nanotechnology-enabled gene delivery for cancer and other genetic diseases
    Tong Jiang, Karina Marie Gonzalez, Leyla Estrella Cordova, Jianqin Lu · 2023 · Expert Opinion on Drug Delivery
15. Tofersen for SOD1 ALS
    William Everett, Robert C. Bucelli · 2024 · Neurodegenerative Disease Management
16. Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis
    Abdullah Ashraf Hamad, Ibraheem M. Alkhawaldeh, Abdulqadir J. Nashwan, Mostafa Mahmoud Meshref, Yahia Zakaria Bashier Imam · 2025 · Neurological Sciences
17. The Inflammatory Puzzle: Piecing together the Links between Neuroinflammation and Amyotrophic Lateral Sclerosis
    Di He, Yan Chun Xu, Mingsheng Liu, Liying Cui · 2023 · Aging and Disease
18. Unraveling the Genetic Landscape of Neurological Disorders: Insights into Pathogenesis, Techniques for Variant Identification, and Therapeutic Approaches
    Zeba Firdaus, Xiaogang Li · 2024 · International Journal of Molecular Sciences
19. Frontotemporal Pathology in Motor Neuron Disease Phenotypes: Insights From Neuroimaging
    Mary Clare McKenna, Philippe Corcia, Philippe Couratier, We Fong Siah, Pierre‐François Pradat, Peter Bede · 2021 · Frontiers in Neurology
20. Amyotrophic Lateral Sclerosis Clinical Trials and Interpretation of Functional End Points and Fluid Biomarkers
    Jeremy M. Shefner, Richard Bedlack, Jinsy A. Andrews, James D. Berry, Robert P. Bowser, Robert H. Brown, Jonathan D. Glass, Nicholas John Maragakis, Timothy M. Miller, Jeffrey D. Rothstein et al. · 2022 · JAMA Neurology
21. Early activation of cellular stress and death pathways caused by cytoplasmic TDP-43 in the rNLS8 mouse model of ALS and FTD
    Wei Luan, Amanda L. Wright, Heledd Brown-Wright, Sheng Le, Rebecca San Gil, Lidia Madrid San Martin, Karen Ling, Paymaan Jafar‐Nejad, Frank Rigo, Adam K. Walker · 2023 · Molecular Psychiatry
22. Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis
    Alexandra Lovett, Sowmya Chary, Suma Babu, Gaëlle Bruneteau, Jonathan D. Glass, Merete Karlsborg, Shafeeq S. Ladha, Keith Mayl, Christopher J. McDermott, Robert C. Bucelli et al. · 2025 · Muscle & Nerve
23. Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy
    M Cappella, Pierre‐François Pradat, Giorgia Querin, Maria Grazia Biferi · 2020 · Journal of Neuromuscular Diseases
24. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial
    Suma Babu, Baileigh G. Hightower, James Gin Man Chan, Nicole R. Zürcher, Pia Kivisäkk, Chieh-En Jane Tseng, Danica L. Sanders, Ashley Robichaud, Haruhiko Banno, Armineuza Evora et al. · 2021 · NeuroImage Clinical
25. A Phase 1 study of GDC ‐0134, a dual leucine zipper kinase inhibitor, in ALS
    Jonathan Katz, Jeffrey D. Rothstein, Merit Cudkowicz, Angela L. Genge, Björn Oskarsson, Avis Brennan Hains, Chen Chen, Joshua Galanter, Braydon L. Burgess, Yong‐Yeon Cho et al. · 2022 · Annals of Clinical and Translational Neurology
26. Biomarkers for amyotrophic lateral sclerosis
    Simon Witzel, Kristina Mayer, Patrick Oeckl · 2022 · Current Opinion in Neurology
27. Approaches to gene modulation therapy for ALS
    Meijboom, Katharina E., Brown, Robert H. · 2022 · Neurotherapeutics
28. Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model
    Marie Dreger, Robert Steinbach, Nayana Gaur, Klara Metzner, Beatrice Stubendorff, Otto Wilhelm Witte, Julian Großkreutz · 2021 · Frontiers in Neuroscience
29. Amyotrophe Lateralsklerose (ALS) – Diagnose, Verlauf und neue Behandlungsoptionen
    Thomas Meyer · 2021 · DMW - Deutsche Medizinische Wochenschrift
30. Astrocytes in Neurodegeneration: Inspiration From Genetics
    Jingxuan Huang, Chunyu Li, Huifang Shang · 2022 · Frontiers in Neuroscience
31. Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
    Virginie Baylot, Thi Khanh Le, David Taïeb, Palma Rocchi, Laurence Colleaux · 2024 · Communications Biology
32. Downregulating PTBP1 Fails to Convert Astrocytes into Hippocampal Neurons and to Alleviate Symptoms in Alzheimer's Mouse Models
    Tiantian Guo, Xinjia Pan, Guangtong Jiang, Denghong Zhang, Jinghui Qi, Lin Shao, Zhanxiang Wang, Huaxi Xu, Yingjun Zhao · 2022 · Journal of Neuroscience
33. The Role of Sphingomyelin and Ceramide in Motor Neuron Diseases
    Gavin McCluskey, Colette G. Donaghy, Karen E. Morrison, John McConville, William John Duddy, Stéphanie Duguez · 2022 · Journal of Personalized Medicine
34. Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection
    Byrnes, Amy E., Dominguez, Sara L., Yen, Chun-Wan, Laufer, Benjamin I., Foreman, Oded, Reichelt, Mike, Lin, Han, Sagolla, Meredith, Hötzel, Kathy, Ngu, Hai et al. · 2023 · Molecular Therapy - Nucleic Acids
35. Genetic epidemiology of familial ALS in Brazil
    João Pedro Nunes Gonçalves, Tauana Bernardes Leoni, Melina P. Martins, Thiago Mazzo Peluzzo, Mário Emílio Teixeira Dourado Júnior, Jonas Alex Morales Saute, Anna Paula Paranhos Miranda Covaleski, Acary Souza Bullé Oliveira, Rinaldo Claudino, Wilson Marques et al. · 2021 · Neurobiology of Aging
36. Current Concepts on Genetic Aspects of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis
    Jankovic, Milena, Novakovic, Ivana, Gamil Anwar Dawod, Phepy, Gamil Anwar Dawod, Ayman, Drinic, Aleksandra, Abdel Motaleb, Fayda I., Ducic, Sinisa, Nikolic, Dejan · 2021 · International Journal of Molecular Sciences
37. ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis
    Jing Jin, Xiao‐bo Zhong · 2023 · Trends in Pharmacological Sciences
38. Clinical and patient‐reported outcomes and neurofilament response during tofersen treatment in SOD1 ‐related ALS —A multicenter observational study over 18 months
    Thomas Meyer, Peggy Schumann, Patrick Weydt, Susanne Petri, Jochen Hans Weishaupt, Ute Weyen, Jan Christoph Koch, René Günther, Martin Regensburger, Matthias Boentert et al. · 2024 · Muscle & Nerve
39. Lipid nanoparticles and transcranial focused ultrasound enhance the delivery of SOD1 antisense oligonucleotides to the murine brain for ALS therapy
    Gayathri R. Ediriweera, Amal J. Sivaram, Gary Cowin, Mikayla L. Brown, Luke McAlary, Jeremy Stephen Lum, Nicholas L. Fletcher, Liam Robinson, Joshua D. Simpson, Liyu Chen et al. · 2024 · Journal of Controlled Release
40. Intrathecal Therapies for Neurodegenerative Diseases: A Review of Current Approaches and the Urgent Need for Advanced Delivery Systems
    Thomas Gabriel Schreiner, Manuel Menéndez‐González, Oliver Daniel Schreiner, Romeo Cristian Ciobanu · 2025 · Biomedicines
41. Cortical progression patterns in individual ALS patients across multiple timepoints: a mosaic-based approach for clinical use
    Marlene Tahedl, Rangariroyashe H. Chipika, Jasmin Lope, Stacey Li Hi Shing, Orla M. Hardiman, Peter Bede · 2021 · Journal of Neurology
42. Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a “real‐world” setting
    Sam Smith, Kelly McCoy‐Gross, Amber Malcolm, Jeri Oranski, Jesse Markway, Timothy M. Miller, Robert C. Bucelli · 2025 · Annals of Clinical and Translational Neurology
43. Defective Oligodendroglial Lineage and Demyelination in Amyotrophic Lateral Sclerosis
    Élisabeth Traiffort, Séverine Morisset‐Lopez, Mireille Moussaed, Amina Zahaf · 2021 · International Journal of Molecular Sciences
44. Breached Barriers: A Scoping Review of Blood-Central Nervous System Barrier Pathology in Amyotrophic Lateral Sclerosis
    Ario Mirian, Alexander Joseph Moszczynski, Serena Soleimani, Isabelle Aubert, Lorne H. Zinman, Agessandro Abrahão · 2022 · Frontiers in Cellular Neuroscience
45. Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months
    Bram De Wel, Maxim De Schaepdryver, Koen Poesen, Kristl G. Claeys · 2022 · Annals of Clinical and Translational Neurology
46. Phosphorylated neurofilament heavy chain: a potential diagnostic biomarker in amyotrophic lateral sclerosis
    Ilana Heckler, Iswariya Venkataraman · 2022 · Journal of Neurophysiology
47. Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double‐blind, placebo‐controlled trial
    Ettore Beghi, Elisabetta Pupillo, Elisa Bianchi, Valentina Bonetto, Silvia Luotti, Laura Pasetto, Caterina Bendotti, Massimo Tortarolo, Francesca M. Sironi, Laura Camporeale et al. · 2022 · European Journal of Neurology
48. Presymptomatic grey matter alterations in ALS kindreds: a computational neuroimaging study of asymptomatic C9orf72 and SOD1 mutation carriers
    Peter Bede, Dorothée E. Lulé, Hans‐Peter Müller, Ee Ling Tan, Johannes Dorst, Albert Christian Ludolph, Jan Kassubek · 2023 · Journal of Neurology
49. LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein
    Zijie Cai, Qianfeng Shi, Yudong Li, Liang Jin, Shunying Li, Lok Lam Wong, Jingru Wang, Xiaoting Jiang, Mengdi Zhu, Jinna Lin et al. · 2023 · Science Advances
50. Neurofilament Biomarkers in Neurology: From Neuroinflammation to Neurodegeneration, Bridging Established and Novel Analytical Advances with Clinical Practice
    Ariadne Daponte, Christos Koros, Charalampos Skarlis, Daphne Siozios, Michail Rentzos, Sokratis G. Papageorgiou, Maria C. Anagnostouli · 2025 · International Journal of Molecular Sciences
51. Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice
    Wei Cheng, Jing Huang, Xiu-Qing Fu, Wei-Ya Tian, Peng-Ming Zeng, Yang Li, Zhen‐Ge Luo · 2023 · Molecular Therapy
52. Alteration of Mitochondrial Integrity as Upstream Event in the Pathophysiology of SOD1-ALS
    René Günther, Arun Pal, Chloe Williams, Vitaly L. Zimyanin, Maria Liehr, Cläre von Neubeck, Mechthild Krause, Mrudula G. Parab, Susanne Petri, Norman Kalmbach et al. · 2022 · Cells
53. Value-Generating Exploratory Trials in Neurodegenerative Dementias
    Lauren G. Friedman, Nicholas McKeehan, Yuko Hara, Jeffrey L. Cummings, Dawn C. Matthews, Jian Zhu, Richard C. Mohs, Deli Wang, Suzanne B. Hendrix, Melanie Quintana et al. · 2021 · Neurology
54. Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions With Neurons
    Elise Liu, Léa Karpf, Delphine Bohl · 2021 · Frontiers in Molecular Neuroscience
55. A copper chaperone–mimetic polytherapy for SOD1-associated amyotrophic lateral sclerosis
    Luke McAlary, Victoria K. Shephard, Gareth S. A. Wright, Justin J. Yerbury · 2022 · Journal of Biological Chemistry
56. In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model
    Yi A. Chen, Mark W. Kankel, Sam Hana, Shukkwan Kelly Lau, Maria I. Zavodszky, Olivia P. McKissick, Nicole Mastrangelo, Jessica Dion, Bin Wang, Daniel Ferretti et al. · 2022 · Gene Therapy
57. The MOE Modification of RNA: Origins and Widescale Impact on the Oligonucleotide Therapeutics Field
    Alyssa C. Hill, Jonathan Hall · 2023 · Helvetica Chimica Acta
58. Therapeutic targeting of ALS pathways: Refocusing an incomplete picture
    Nicholas John Maragakis, Mamede A. de Carvalho, Michael D. Weiss · 2023 · Annals of Clinical and Translational Neurology
59. Advances and Challenges in Gene Therapy for Neurodegenerative Diseases: A Systematic Review
    Nerea García-González, Jaime Gonçalves-Sánchez, Ricardo Gómez‐Nieto, Jesús María Gonçalves, Dolores E. López · 2024 · International Journal of Molecular Sciences
60. Parkinson’s disease therapy: what lies ahead?
    Andreas Wolfgang Wolff, Nicolas U Schumacher, Dominik Pürner, Gerrit Machetanz, Antonia Franziska Demleitner, Emily Feneberg, Maike Hagemeier, Paul Lingor · 2023 · Journal of Neural Transmission
61. Astrocytes: Dissecting Their Diverse Roles in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
    Valori, Chiara F., Sulmona, Claudia, Brambilla, Liliana, Rossi, Daniela · 2023 · Cells
62. Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients
    Mario Sabatelli, Federica Cerri, Riccardo Zuccarino, Agata Katia Patanella, Daniela Bernardo, Giulia Bisogni, Raffaella Tanel, Valeria Sansone, Massimiliano Filosto, Serena Lattante et al. · 2024 · Journal of Neurology
63. Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation
    Rachael Miller, Joseph D. Paquette, Alexandra Barker, Ellen Sapp, Nicholas McHugh, Brianna M. Bramato, Nozomi Yamada, Julia F. Alterman, Dimas Echeverria, Ken Yamada et al. · 2024 · Molecular Therapy — Nucleic Acids
64. The blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases
    Christian Barro, Henrik Zetterberg · 2021 · Journal of Neuroscience Methods
65. Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis
    Stephanie R. Shepheard, Vassilios Karnaros, Beben Benyamin, David W Schultz, Megan Fowler, Joanne Wuu, Tim Chataway, Andrea Malaspina, Michael G Benatar, Mary‐Louise Rogers · 2021 · European Journal of Neurology
66. Status of ALS treatment, insights into therapeutic challenges and dilemmas
    Khamaysa, Mohammed, Pradat, Pierre-François · 2022 · Journal of Personalized Medicine
67. Antisense therapies in neurological diseases
    J.-B. Brunet de Courssou, Alexandra Dürr, David Adams, Jean‐Christophe Corvol, Louise‐Laure Mariani · 2021 · Brain
68. SYF2 suppression mitigates neurodegeneration in models of diverse forms of ALS
    Gabriel R. Linares, Yichen Li, Wen-Hsuan Chang, Jasper Rubin-Sigler, Stacee Mendonca, Sarah Hong, Yunsun Eoh, Wenxuan Guo, Yi‐Hsuan Huang, Jonathan Chang et al. · 2023 · Cell stem cell
69. Amyotrophic lateral sclerosis
    David S. Younger, Robert H. Brown · 2023 · Handbook of clinical neurology
70. Efficacy and safety of a SOD1-targeting artificial miRNA delivered by AAV9 in mice are impacted by miRNA scaffold selection
    Shukkwan K. Chen, Zachary C. E. Hawley, Maria I. Zavodszky, Sam Hana, Daniel Ferretti, Branka Grubor, Michael C. Hawes, Shanqin Xu, Stefan Hamann, Galina Marsh et al. · 2023 · Molecular Therapy — Nucleic Acids
71. The new direction of drug development: Degradation of undruggable targets through targeting chimera technology
    Xuewu Liang, Hairu Ren, Fengyang Han, Renwen Liang, Jiayan Zhao, Hong Liu · 2023 · Medicinal Research Reviews
72. Activating autophagy to eliminate toxic protein aggregates with small molecules in neurodegenerative diseases
    Yuqi Fu, Jin Zhang, Rui Qin, Yueting Ren, Tingting Zhou, Bo Han, Bo Liu · 2025 · Pharmacological Reviews
73. Blood β-Synuclein and Neurofilament Light Chain During the Course of Prion Disease
    Steffen Halbgebauer, Samir Abu‐Rumeileh, Patrick Oeckl, Petra Steinacker, Francesco Roselli, Diana Wiesner, Angela Mammana, Michael Beekes, Izaro Kortazar Zubizarreta, Guiomar Pérez de Nanclares et al. · 2022 · Neurology
74. Prionoids in amyotrophic lateral sclerosis
    Philippe Gosset, William Camu, Cédric Raoul, Alexandre Mezghrani · 2022 · Brain Communications
75. Intercellular transmission of pathogenic proteins in ALS: Exploring the pathogenic wave
    Frederick J. Arnold, Ashlie Nguyen, Richard Bedlack, Craig L. Bennett, Albert R. La Spada · 2023 · Neurobiology of Disease
76. Metabolic Transporters in the Peripheral Nerve—What, Where, and Why?
    Atul Kumar Rawat, Brett M. Morrison · 2021 · Neurotherapeutics
77. Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS
    Meredith A Mortberg, Hien Tran Zhao, Andrew G. Reidenbach, Juliana E Gentile, Eric W. Kuhn, Jill O’Moore, Patrick M. Dooley, Theresa R. Connors, Curt Mazur, Shona W. Allen et al. · 2022 · JCI Insight
78. Potential of Cellular Therapy for ALS: Current Strategies and Future Prospects
    Ting-Jung Lin, Kuang-Chao Cheng, Luo-Yun Wu, Wei-Yu Lai, Thai‐Yen Ling, Yung‐Che Kuo, Yen‐Hua Huang · 2022 · Frontiers in Cell and Developmental Biology
79. Single Stranded Fully Modified-Phosphorothioate Oligonucleotides can Induce Structured Nuclear Inclusions, Alter Nuclear Protein Localization and Disturb the Transcriptome In Vitro
    Loren L. Flynn, Ruohan Li, Ianthe L. Pitout, May Thandar Aung-Htut, Leon M. Larcher, Jack A. L. Cooper, K. Greer, Alysia Hubbard, Lisa Griffiths, Charles S. Bond et al. · 2022 · Frontiers in Genetics
80. Clinical and genetic features of amyotrophic lateral sclerosis patients withC9orf72mutations
    Maximilian Wiesenfarth, Kornelia Günther, Kathrin Müller, Simon Witzel, Ulrike Weiland, Kristina Mayer, Christine H. Herrmann, Dávid Brenner, Joachim Schuster, Axel Freischmidt et al. · 2023 · Brain Communications
81. Limited value of serum neurofilament light chain in diagnosing amyotrophic lateral sclerosis
    Jennifer C. Davies, Thanuja Dharmadasa, Alexander G. Thompson, Evan Edmond, Katie Tharshana Yoganathan, Jiali Gao, Kevin Talbot, Martin R. Turner · 2023 · Brain Communications
82. Cerebrospinal Fluid and Blood Neurofilament Light Chain Protein in Prion Disease and Other Rapidly Progressive Dementias: Current State of the Art
    Samir Abu‐Rumeileh, Piero Parchi · 2021 · Frontiers in Neuroscience
83. Consideration of C9orf72-associated ALS-FTD as a neurodevelopmental disorder: insights from neuroimaging
    Peter Bede, We Fong Siah, Mary Clare McKenna, Stacey Li Hi Shing · 2020 · Journal of Neurology Neurosurgery & Psychiatry
84. Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
    Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld · 2021 · International Journal of Molecular Sciences
85. Why TDP-43? Why Not? Mechanisms of Metabolic Dysfunction in Amyotrophic Lateral Sclerosis
    Mara-Luciana Floare, Scott P. Allen · 2020 · Neuroscience Insights
86. Advances in the genetic classification of amyotrophic lateral sclerosis
    Johnathan Cooper‐Knock, Calum Harvey, Sai Zhang, Tobias Moll, Ilia Sarah Timpanaro, Kevin Patrick Kenna, Alfredo Iacoangeli, Jan Herman Veldink · 2021 · Current Opinion in Neurology
87. Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis
    Lien Nguyen · 2024 · Cells
88. Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: A Story of Hope Turned to Disappointment in Amyotrophic Lateral Sclerosis Treatment
    Arsh Haj Mohamad Ebrahim Ketabforoush, Faezeh Faghihi, Fereshteh Azedi, Armin Ariaei, Mohamad Amin Habibi, Maryam Khalili, Bahram Haghi Ashtiani, Mohammad Taghi Joghataei, William David Arnold · 2024 · Clinical Drug Investigation
89. Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients
    Lars Hendrik Müschen, Alma Osmanovic, Camilla Binz, Konstantin Fritz Jendretzky, Gresa Ranxha, Paul Bronzlik, Omar Abu-Fares, Flavia Wiehler, Nora Möhn, Martin Werner Hümmert et al. · 2021 · Brain Sciences
90. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases
    Pandey, Manish, Ojha, Divya, Bansal, Sakshi, Rode, Ambadas B., Chawla, Geetanjali · 2021 · Molecular Aspects of Medicine
91. Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?
    Bradley Roberts, Frances Theunissen, Francis L. Mastaglia, Patrick Anthony Akkari, Loren L. Flynn · 2022 · International Journal of Molecular Sciences
92. Prospects for gene replacement therapies in amyotrophic lateral sclerosis
    Ilaria Giovannelli, Adrian Higginbottom, Janine Kirby, Mimoun Azzouz, Pamela J. Shaw · 2022 · Nature Reviews Neurology
93. Intrathecal administration of a novel siRNA modality extends survival and improves motor function in the SOD1G93A ALS mouse model
    Chunling Duan, Moorim Kang, Xiaojie Pan, Zubao Gan, Vera Huang, Guanlin Li, Robert F. Place, Long‐Cheng Li · 2024 · Molecular Therapy — Nucleic Acids
94. CSF neurofilament light chain profiling and quantitation in neurological diseases
    Claire Alexandra Leckey, John B. Coulton, Tatiana A. Giovannucci, Yingxin He, Aram Aslanyan, Rhiannon Laban, Amanda Heslegrave, Ivan Doykov, Francesca Ammoscato, Jeremy Chataway et al. · 2024 · Brain Communications
95. Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen
    Hidenori Moriyama, Toshifumi Yokota · 2024 · Genes
96. Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients
    Qingjian Xie, Kezheng Li, Yinuo Chen, Yaojia Li, Wenhua Jiang, Wen Cao, Huan Yu, Dongsheng Fan, Binbin Deng · 2025 · Translational Neurodegeneration
97. FGF23, a novel muscle biomarker detected in the early stages of ALS
    Ying Si, Mohamed Kazamel, Michael G Benatar, Joanne Wuu, Yuri Kwon, Thaddaeus Kwan, Nan Jiang, Dominik Kentrup, Christian Faul, Lyndsy Alesce et al. · 2021 · Scientific Reports
98. Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes
    Antonio Canosa, Andrea Calvo, Cristina Moglia, Rosario Vasta, Francesca Palumbo, Luca Solero, Francesca Di Pede, Sara Cabras, Vincenzo Arena, Grazia Zocco et al. · 2022 · European Journal of Nuclear Medicine and Molecular Imaging
99. The landscape of cognitive impairment in superoxide dismutase 1-amyotrophic lateral sclerosis
    Ilaria Martinelli, Elisabetta Zucchi, Cecilia Simonini, Giulia Gianferrari, Giovanna Zamboni, Marcello Pinti, Jessica Mandrioli · 2022 · Neural Regeneration Research
100. Palliative care principles in ALS
     Christen L. Shoesmith · 2023 · Handbook of clinical neurology